Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes: - the new IMWG SLiM CRAB criteria - the latest advances in diagnostic tests and imaging - cytogenetics and genetic profiling - induction therapy prior to SCT - new lenalidomide- and bortezomib-based regimens - second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments. This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice. Contents: • Epidemiology and etiology Predisposing conditions associated with MM • Pathophysiology of MM and MGUS • Diagnosis, staging and monitoring of multiple myeloma • Genetics and multiple myeloma • Treatment of newly diagnosed multiple myeloma • Stem cell transplantation in multiple myeloma • Relapsed and refractory multiple myeloma • Bone disease and renal complications • AL amyloidosis • Rare plasma cell dyscrasias • Supportive care

Preceded by: Clinical clerkship in inpatient medicine / Sanjay Saint. 3rd ed. c2010.

This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment.

Multiple Myeloma accounts for approximately 0.8% of cancers worldwide, with about 114 000 new cases each year. Rapid progress is being made in the development of new treatments and, although myeloma is incurable at present, survival has almost tripled over the past 10 years and it is now projected that a third of patients will survive more than 10 years after diagnosis.Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias emphasizes the importance of early diagnosis for a favourable outcome, covers the ever-increasing role of genetics in diagnosis and treatment, and discusses new and gold-standard treatments. A chapter on supportive care also features and briefs the healthcare professional on long-term outcomes and quality of life issues. Primarily intended for primary care providers, specialist nurses, junior doctors and allied healthcare professionals, this highly readable resource provides a comprehensive overview of myeloma and other plasma cell dyscrasias, from bench to bedside, putting the pathogenesis, diagnosis and treatment of these disorders in the context of daily clinical practice.

Information + Taking Control = Best Outcome is the theme running through this short, superbly illustrated workbook, which is designed to help patients equip themselves with the best information about myeloma. Starting with a simple overview of the biology of the disease, this comprehensive resource will also help patients to understand the type of myeloma that they have, the remitting-relapsing nature of the disease, and the signs and symptoms they are likely to experience. 'Fast Facts: Myeloma for Patients and their Supporters' takes patients through the initial treatment options and their side effects, what to expect if they have stem cell transplantation, and how they will be treated when their symptoms return. The final sections will help patients understand what supportive care options are available to them, and provide an insight into the latest myeloma research, which is progressing on many fronts. With FastTests to test patients' understanding of their condition throughout, and plenty of space for patients to write their own notes, this concise, easy-to-read resource will help patients get organized so that they are better equipped to ask the right questions and have more meaningful discussions with their doctors and nurses. Ultimately, it will help them make the best decisions about their care. Contents: • Information + Taking Control = Best Outcome • What is myeloma? • Who gets myeloma and why? • How is myeloma diagnosed? • What type of myeloma do I have? • What are the effects of myeloma? • What is staging and why is it done? • What initial treatment will I receive? • Stem cell transplantation • Monitoring the effects of therapy • Treatment when myeloma returns • Supportive care • Research to follow and support • Useful resources

Lymphoma can be broadly defined as a cancer of mature lymphocytes. Our understanding of the biology of normal lymphocytes and lymphoma has grown at a tremendous pace, and this is now directly translating into changes in clinical practice. This became evident with the introduction of one of the first therapeutic monoclonal antibodies into cancer medicine, the CD20-directed antibody rituximab, which has led to significant benefit for patients with B-cell lymphomas. Since then, a raft of novel agents has entered clinical practice, including targeted small molecules, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cells. This new edition of 'Fast Facts: Lymphoma' has been updated to include recent changes in our understanding of lymphoma biology as well as improvements in diagnostics and therapeutics.

Effective new treatments - from drugs to surgery to devices - are revolutionizing both outcome and wellbeing in patients with heart failure. Written with the non-specialist in mind, this practical resource distills a lot of complex information into a refreshingly readable format, with clear informative diagrams and useful pull-out tables. Highlights include: • a concise discussion of the pathophysiological mechanisms that lead to heart failure • a detailed review of the causes and comorbidities of heart failure • simple advice on diagnosis and investigation • clear management principles, including healthy lifestyle choices for patients • evidence-based guidance on first- and second-line drug therapies and medical management that targets the underlying cause • a comprehensive overview of non-pharmacological treatment options, including devices and transplantation • important information on palliative care in end-stage heart failure. 'Fast Facts: Heart Failure' is the ideal resource for primary care providers, specialist nurses and cardiology trainees, and a good introduction to heart failure for all healthcare professionals who care for the elderly. Contents: • Definitions and epidemiology • Pathophysiology and clinical stages • Causes • Comorbidities • Diagnosis • General management and lifestyle considerations • Pharmacological treatment • Non-pharmacological treatment • Prognosis • Clinical trials and developments • Useful resources

Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

Cancer and the Kidney covers the challenging overlap area of nephrology and oncology, both in terms of kidney problems in cancer patients, and cancer that affects kidney patients, including assessment of kidney function, to paraneoplastic disorders, acquired cysts and native kidney cancers, and all points inbetween.

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.